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Introduction
Coronary artery (CABG) and peripheral vascular bypass 
grafting (PVBG) are currently the most effective treatment 
to normalize blood supply to the ischemic myocardium or 
limbs following severe coronary or peripheral vascular 
atherosclerosis. To this end, various conduits are used 
including autologous vessels or synthetic grafts such as 
polytetrafluoroethylene or polyethylene terephthalate. The 
internal mammary artery (IMA) is the gold standard autol-
ogous conduit for CABG surgery improving long-term 
survival and life expectancy by ensuring a patency rate of 
85% at 10 years.1 Yet, >70% of CABG grafts are based on 
the use of autologous greater saphenous vein (SVG), 
which, along with synthetic grafts, is the only available 
option for PVBG surgery.2 However, 15% to 20% of SVG 
grafts suffer early thrombosis at 1 year and 50% are 
occluded at 10 years due to thrombosis or intimal hyper-
plasia.3 A large proportion of synthetic and venous grafts 
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Human saphenous vein (hSV) and synthetic grafts are commonly used conduits in vascular grafting, despite high failure rates. 
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used for PVBG get blocked at 2 to 4 years due to excessive 
thrombogenicity and complications from infection, with 
the patency steadily decreasing over time.2 The sub-opti-
mal performance of SVG and synthetic grafts makes more 
effective conduits desperately needed.
Vascular tissue engineering involves biomaterials, cells 
and regulatory signals, and relies on optimisation of bio-
mechanical cues and tissue architecture, including strate-
gies for manufacturing small (<6 mm diameter) tissue 
engineered vascular grafts (TEVG).4,5 TEVGs have been 
developed using either ex vivo scaffolds seeded with cells 
and/or growth factors or biohybrid tissue with or without 
cell stripping (decellularisation). Decellularisation aims to 
remove the cellular components to prevent immune rejec-
tion or tissue mis-match at transplantation while preserv-
ing the extracellular matrix (ECM) and structural integrity. 
It is being used to bio-engineer skin, pericardium, heart 
valves and blood vessels6–8 with claimed advantages over 
synthetic materials being superior biocompatibility and 
reduced infections.9,10 However, concerns remain on the 
safety of decellularisation methods, cytotoxicity, biocom-
patibility as well as the clinical applicability in preclinical 
models highly relevant to humans.11–13 Effective decellu-
larisation should aim for lack of residual viable cells and 
nuclear material, ECM integrity, <50 ng deoxyribonucleic 
acid (DNA) per mg dry weight ECM, and <200 base pairs 
of double stranded DNA (dsDNA) fragment length.8,14 
Methods might differ based on type and size of tissue or 
organ to be decellularised.
It is suggested that key aspects of the ideal TEVG 
include biocompatibility, mechanical properties similar to 
arteries, readily available, low manufacturing costs, easy 
storage and be sterilisable.15
In this study, we used adapted mechanical and chemical 
methods described by others16 to effectively decellularise 
human SV (D-hSV) while keeping them biocompatible. 
Mechanical safety, biocompa tibility, immunogenicity and 
surgical feasibility of the modified protocol were tested in 
vitro and in vivo using a porcine model of carotid artery 
replacement with no immuno suppression.
Methods
Human and porcine tissue collection
Segments of human SV left over from CABG surgery at 
the Bristol Heart Institute, Bristol, UK, were collected 
under sterile conditions and stored in either saline or 
Dulbecco’s modified Eagle's medium (DMEM) (Sigma) 
containing Penicillin-Streptomycin (200 μg/mL, Sigma); 
GlutaMAX™-I Supplement (2 mM, Sigma) stored at 4°C 
until decellularisation. Pre-decellularisation segments 
were retained (control) fixed in 10% formalin (Sigma) at 
4°C for comparative histological analysis. Human tissue 
was obtained in accordance with ethical approval from the 
local committee (REC reference number: 10/H0107/63).
Fresh porcine carotid artery (pCA) were harvested under 
clinical conditions from control animals undergoing 
termination procedures (under Home Office license PPL: 
30/2854) at the Translational Biomedical Research Centre 
(TBRC), Bristol, UK. These were placed in 50 mL Falcon 
tubes containing sterile DMEM supplemented as above and 
transported to the laboratory for processing to isolate endothe-
lial (PCAEC) and smooth muscle (PCASMC) cells, as fol-
lows. After removal of surrounding adventitial tissue from 
pCA, vessels were cut longitudinally and PCAEC isolated by 
scraping the lumen with a scalpel. Cells were transferred to 
Endothelial Cell Growth Medium MV2 (Promocell), spun, 
resuspended and seeded on fibronectin-coated (100 µg/mL, 
Sigma) 6-well plates for culture (5% CO2 at 37°C). PCAECs 
were maintained until cells were 70-80% confluent before 
trypsinization for further analysis. PCASMC were cultured 
and expanded from 1 mm2 explants of the medial layer of 
vessels in Smooth Muscle Cell Growth Medium 2 
(Promocell). Both cell types underwent standard culture pro-
cedures until use.
SDS Cytotoxicity and optimisation of 
concentration
An initial stock solution of 1% SDS (w/v; Fisher Scientific) 
as highest concentration was made in sterile PBS, which 
equates to a 35 mM solution, and filtered through a 0.2 µm 
syringe filter. This stock was diluted further to achieve the 
decremental concentrations required (Supplemental Table 1). 
To ascertain the minimal non-cytotoxic concentration, SDS 
was added to fresh PCAECs and PCASMCs. The number of 
proliferating and viable cells was determined using EdU and 
AlamarBlue assay respectively, as described in the supple-
mentary methods section.
Optimisation of human saphenous vein 
decellularisation
To determine the optimum SDS concentration for successful 
decellularisation, hSV (n = 6) were cut into rings (0.5 cm 
length) placed in 5 mL increasing SDS concentrations (0.01; 
0.025; 0.05; 0.075 and 0.1% (w/v in PBS)) and agitated on a 
tube roller (60 rpm, Stuart, UK) for 24 h at room temperature. 
SDS treated segments were transferred to PBS (Sigma) on the 
roller at room temperature with PBS changes after 24 h (Wash 
1) and 48 h (Wash 2) before final storage in fresh sterile PBS 
at 4°C. To assess whether our protocol would translate to 
clinically relevant lengths of vein, we also undertook decel-
lularisation of longer (4–6 cm) hSV segments. Obtained hSVs 
were divided into two pieces and placed either in 40 mL 
0.01% SDS (w/v) on a tube roller (at 60 rpm) (D-hSVROLLER) 
or cannulated and placed in a dynamic flow setup with 
120 mL of 0.01% SDS (w/v) constantly recirculated for 24 h 
at room temperature through the vessel lumen, using a peri-
staltic pump at a flow rate of 6 mL/min (D-hSVFLOW). Next, 
SDS was replaced with PBS for two 24-h washes at room 
temperature. The efficacy of the decellularisation process was 
assessed as described for 0.5 cm segments with comparisons 
made versus long hSV controls and versus short D-hSVs.
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Evaluation of effectiveness of decellularisation
Formalin-fixed paraffin embedded transverse sections 
(FFPE; 5 µm thick) were stained with H&E to detect cell 
nuclei in the intima, media and adventitia by automated 
image analysis (ImageJ software) in four quadrants of four 
transverse sections (total of 16 counts). Counts were aver-
aged for each untreated hSV control (n = 10) and each decel-
lularised hSV segment (n = 10). The percentage of 
decellularisation was calculated compared to native control.
Double-stranded DNA content of tissue homogenates of 
native control versus decellularised hSVs (n = 10 per treat-
ment) was assessed with a Quant-iT PicoGreen assay (Life 
Technologies) as described in the supplementary methods.
For long hSVs, to confirm that residual cell debris was 
non-proliferative, a BrdU cell proliferation assay was per-
formed on D-hSVs on the roller with 0.01% SDS (w/v) 
(n = 5). Two cm segments of either native or D-hSVROLLER 
were cut open longitudinally to expose the whole lumen 
and pinned into a culture dish containing Sylgard resin. 
Opened D-hSV-roller were cultured for 14 days in RPMI 
1640 containing 30% FCS, L-Glutamine, gentamicin, pen-
icillin and streptomycin, and 10 µM BrdU (Sigma) (at 
37°C, 5% CO2) with media changes every 2 to 3 days, 
before being fixed and paraffin embedded. Samples of 
native controls and D-hSVs were fixed at Day 0 to serve as 
control. Sections (5 µm thick) were probed with a mouse 
anti-BrdU antibody (Sigma, UK) and the percentage of 
BrdU positive cells calculated.
Preservation of extracellular matrix integrity
hSVs before and after SDS treatment (n = 6 per treatment 
group) were compared with regard to content of hydroxy-
proline (Sigma), elastin (FastinTMElastin kit, Biocolor) and 
glycosaminoglycans (GAGs, Blyscan Assay Kit, Biocolor). 
Assays were performed according to manufacturer’s instruc-
tions on approximately 10 mg of tissue following treatment 
with 0, 0.01, 0.025, 0.025, 0.075 and 0.1% w/v SDS. All 
data were normalised to the total wet protein content of tis-
sue, as determined by Pierce Detergent Compatible Bradford 
Assay (ThermoFisher, UK). In addition, FFPE transverse 
sections (5 µm thick) through the conduit were stained with 
picrosirius red (PSR), elastin van gieson (EVG) and alcian 
blue for evaluation of collagen, elastin and GAGs respec-
tively. The percentage area of tissue staining for elastin, col-
lagen and GAGs was determined by counting the number of 
pixels stained for each ECM component, within four quad-
rants in four transverse sections, and counted using auto-
mated image analysis software (ImageJ).
Biocompatibility of decellularised hSVs
The viability of human adipose-derived stem cells (ADSC; 
Lonza), human umbilical vein endothelial cells (HUVEC; 
PromoCell), and human saphenous vein smooth muscle 
cells (HSVSMC; isolated using method described previ-
ously for PCASMC) seeded onto the D-hSVs was assessed 
with AlamarBlue (for details see supplementary methods).
To assess differences in biocompatibility between 
D-hSVROLLER and D-hSVFLOW these were seeded with 
5 × 104 pCA ECs for 48 h, and then formalin-fixed before 
subsequently being stained with H&E, or immunostained 
with an endothelial cell marker (rabbit polyclonal to CD31 
antibody; 0.9 µg/ml; Abcam, Ab28364) followed by a 
Alexa-Fluor 488 secondary antibody (chicken polyclonal 
anti-rabbit IgG; 10 µg/ml, ThermoFisher Scientific, 
A-21441), and a smooth muscle cell marker (mouse anti-
actin, monoclonal 1A4, alpha smooth muscle-Cy3 anti-
body; 3 µg/ml; Sigma, C6198). Native hSV tissue was 
used as control.
Quantification of residual SDS on decellularised 
hSVs
During the decellularisation process with 0.01% SDS, ali-
quots of every effluent (0.01% SDS, PBS Wash 1 and 
Wash 2) were collected after each step during both roller 
and flow protocols (n = 8 per protocol). The same hSVs 
(n = 5) were divided in two and subjected to either roller or 
flow protocols. Following decellularisation and washing 
steps, the concentration of SDS remaining was analysed 
using a methylene blue assay (see supplementary methods 
section).
Mechanical strength testing before and after 
decellularisation
D-hSV in 0.01% SDS (w/v) (n = 5; D-hSVROLLER), non-
treated hSV control (n = 5), and porcine carotid artery 
(PCA; n = 5, as an arterial control) were stored in PBS 
(containing 0.02% Sodium Azide), before being mechani-
cally tested at the ISO accredited testing facility (Amrita 
Centre for Nanosciences and Molecular Medicine, India). 
Burst pressure was calculated by inflating the conduits 
with water at a steady rate until the burst pressure was 
reached. The radial compliance was calculated by measur-
ing the internal diameter change with a laser micrometer at 
pressures between 110 and 150 mmHg (conduits inflated 
with air); results are presented as percentage of diameter 
change per 100 mmHg.
Assessment of mechanical strength, 
biocompatibility and patency rates in vivo
Following decellularisation on a roller with 0.01% SDS 
(w/v), D-hSV (2 cm length) were stored in sterile PBS at 
4°C. In vivo transplantation was carried out at the advanced 
TBRC facility for large animals (as described in 
Supplementary methods), in female Landrace pigs (n = 6; 
mean weight 58.8 ± 1.4 kg), under strict clinical standards 
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including anti-platelet therapy (first three pigs received 
75 mg aspirin with food from 5 days before surgery till ter-
mination; the subsequent three pigs received 300 mg aspi-
rin at the same time points) and anticoagulation with 
heparin to keep the activated clotting time > 250 s. Pigs 
were recovered and maintained under optimal animal wel-
fare conditions for 4 weeks. After this period of mainte-
nance, animals were subjected to general anaesthesia and 
mechanical ventilation. The implanted grafts were surgi-
cally exposed and evaluated. Next, they were excised, and 
formalin fixed, along with a section of the proximal and 
distal carotid artery and sectioned at 5 µm thickness. 
Sections were stained with H&E and EVG to analyse con-
duit lumen diameter and wall thickness (ImageJ Software).
Statistics
All data is presented as mean ± SEM, and statistical anal-
ysis was performed using GraphPad Prism (GraphPad 
Software, California, USA), with differences between 
groups/treatments deemed significant if p < 0.05. The sta-
tistical test used for each comparison is shown in 
Supplementary Table 2.
Results
SDS Cytotoxicity and optimisation of 
concentration
Higher SDS concentrations reduced the proliferation and 
viability of PCAECs and PCASMCs (Table 1). PCAECs 
viability dropped below 70% at SDS concentrations 
⩾0.00025%, although it was not until 0.005% that viabil-
ity was significantly decreased (p < 0.01). At SDS concen-
trations <1.0 × 10–4% PCAECs proliferation was higher 
than the threshold viability (p < 0.05), but it dropped 
below 70% at 7.5 × 10–4%, with no proliferation at all 
observed at 2.5 × 10–3% (87 µM). PCASMCs tolerated 
higher SDS concentrations with proliferation and viability 
falling below 70% at ⩾7.5 × 10–4% and ⩾5.0 × 10–4, 
respectively.
Efficacy of decellularisation methods used
In short D-hSV segments (~0.5 cm) all SDS concentrations 
tested reduced the number of nuclei detected compared to 
controls (p < 0.001; Figure 1(a)), with the staining inten-
sity of the residual nuclei being decreased (Figure 1(b)). 
While dsDNA content within the D-hSV did not differ 
from control for any of the SDS concentrations used 
(p > 0.05, n = 6; Figure 2(a)), most of the high molecular 
weight DNA had disappeared with 0.01% (w/v) SDS, 
when samples underwent agarose gel electrophoresis 
(n = 3; Figure 2(b)). No proliferating cells were detected by 
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Figure 1. Efficiency of the decellularisation protocol with various SDS concentrations. Decellularisation protocol optimisation 
using 0.01, 0.025, 0.05, 0.075 and 0.1% SDS (w/v) compared to native control hSV. (a) Percentage of decellularisation was calculated 
by quantifying the nuclei (purple-black) in H&E stained FFPE sections of decellularised compared to native veins (n = 6). Values are 
presented as mean ± SEM, *indicates p < 0.001. (b) Representative images of decellularised and native veins stained with H&E. Scale 
bars represent 350 μm and 200 μm as marked.
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Figure 2. Effect of SDS treatment on DNA content. (a) PicoGreen assay to quantify dsDNA in native (control) hSV and following 
treatment in SDS concentrations of 0.01% to 0.1% (w/v) (n = 6). Values are presented as mean ± SEM. (b) Percentage of high 
molecular weight DNA in 0.01% decellularised and native tissues (n = 3) in agarose gel electrophoresis with a representative gel 
electrophoresis image of native hSV (Native) and 0.01% (w/v) SDS decellularised hSV.  
* indicates p<0.01 versus native DNA. 
SDS (the lowest concentration used) after 14 days in cul-
ture vs 81.0 ± 4.8% in controls (p < 0.0001; Figure 3).
As the results of 0.01% SDS (w/v) on short D-hSV 
were more encouraging than higher concentrations, we 
used next 0.01% SDS (w/v) to decellularise longer (4–
6 cm) hSV segments to enhance translation. Long hSVs 
were exposed to 0.01% SDS on a roller and in a perfusion 
chamber setup. Decellularisation by flowing reduced the 
percentage of nuclei by 21.4 ± 3.1% versus controls 
(p < 0.05), whereas the rolling method reduced this by 
56.3 ± 14.2%; p < 0.001 versus controls; Figure 4(a)). 
There was reduction of DNA content with both methods, 
but this did not reach significance (p > 0.05, Figure 4(b)).
For in vitro biocompatibility testing, opened D-hSVs-
ROLLER were seeded with ADSC, HUVEC and HSVSMC 
(n = 6 D-hSV per cell type). After 24 h, all cell types were 
Figure 3. Detection of percentage of proliferating cells in 
organ cultures (n = 5), assessed by BrdU incorporation in 
native hSV and following treatment with 0.01% (w/v) SDS. 
*indicates p < 0.0001.
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Figure 4. Effectiveness of decellularisation: flow versus roller protocols. (a) The percentage of decellularisation was calculated 
by quantifying the nuclei (blue) in H&E stained sections of decellularised and native veins. Representative images of native hSV 
and 0.01% SDS (w/v) flow versus roller decellularised hSVs are shown (n = 6). Scale bar represents 300 μm. (b) PicoGreen assay 
quantification of dsDNA from native hSVs and following decellularisation in 0.01% SDS (w/v) under flow or roller conditions 
(n = 10). Values are presented as mean ± SEM, *indicates p < 0.01.
viable, with ADSCs and HSVSMCs increasing their num-
ber over time (ADSC: 757 ± 741 to 3717 ± 1617 
(p < 0.05); HUVEC: 2728 ± 707 to 2702 ± 1291 
(p > 0.05); HSVSMC: 3559 ± 533 to 7836 ± 1587 
(p < 0.05), 24–72 h, respectively) (Figure 5). Both 
D-hSV-ROLLER and D-hSVFLOW seeded with pCA-ECs 
showed positive H&E nuclei staining and positive staining 
for CD31 (Figure 6). In D-hSVROLLER H&E staining 
showed some nuclei within the tissue along with some 
positive staining for CD31 and αSMA.
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Figure 5. Cell viability of human adipose-derived stem cells (ADSC), umbilical vein endothelial cells (HUVEC) and saphenous vein 
smooth muscle cells (HSVSMCs) seeded onto hSV segments treated with SDS (0.01% w/v), and cultured for 24 and 72 h. The cell 
number was estimated with the Alamar Blue assay (n = 4). Values are presented as mean ± SEM, *indicates p < 0.05.
Figure 6. Assessment of biocompatibility using endothelial cell seeding and histological analyses. (a) Representative images of H&E 
stained sections of (i) native hSV, (ii) flow and (iii) roller decellularised hSVs that were seeded with pCAEC for 48 h. Black arrow 
showing nuclei. Scale bars represent 200 μm. (b) Representative images of dual immunohistochemistry for αSMA (red arrow) and 
CD31 (green arrow head and arrow) in (i) flow decellularised hSV; and the seeded (ii) flow and (iii) roller decellularised hSVs. 
Nuclei are stained with DAPI (blue arrow). Scale bars represent 300 μm.
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Preservation of ECM integrity
The analysis of tissue digests for short hSVs (~0.5 cm) 
showed that the hydroxyproline content of D-hSV was sig-
nificantly decreased compared to untreated hSVs when 
exposed to SDS concentrations of 0.05% (w/v) and above 
(p < 0.05), whereas no significant changes were observed 
in elastin or GAG content. Pixel counting of stained D-hSV 
with PSR, EVG and alcian blue showed no significant 
reduction in collagen, elastin or GAGs content respec-
tively, compared to untreated hSV (p > 0.05) (Table 2). In 
long D-SVs the content of hydroxyproline, elastin and 
GAG was not affected by 0.01% SDS (w/v) compared to 
controls for both D-hSVROLLER or D-hSVFLOW protocols 
(n = 7, p > 0.05) (Table 3).
Mechanical testing
The burst strength of D-hSV treated with 0.01% SDS (436 
± 176.3 kPa; n = 5) was not significantly different from 
either untreated hSV controls (364 ± 209.4 kPa; p > 0.05, 
n = 5), untreated porcine carotid artery (537 ± 73 kPa; 
p > 0.05, n = 4) or synthetic PTFE (863.7 ± 36.2 kPa, 
p > 0.05, n = 3) (Figure 7(a)). The compliance of native 
hSV (12.9 ± 3.7%/100 mmHg, n = 5), PCA (13.7 ± 
5.5%/100 mmHg, n = 4) and synthetic PTFE (1.6 ± 0.11 
5%/100 mmHg, p > 0.05, n = 3) were also not significantly 
different from the D-hSV (D-hSV: 16.0 ± 4.5 
%/100 mmHg, p > 0.05, n = 5) (Figure 7(b)).
Residual SDS concentration
Methylene Blue analysis of the effluent from D-hSVFLOW 
and D-hSVROLLER (Figure 8(a)) showed that SDS was still 
detected in the first (D-hSVFLOW: 0.0016 ± 0.0003%; 
D-hSVROLLER: 0.0015 ± 0.0002% D-hSVROLLER) and sec-
ond (D-hSVFLOW: 0.0003 ± 0.0000%; D-hSVROLLER: 
0.0003 ± 0.0000% D-hSVROLLER) PBS washes, but these 
were both significantly reduced compared to the SDS 
effluent (D-hSVFLOW: 0.0098 ± 0.0007%; D-hSVROLLER: 
0.0095 ± 0.0006%, p < 0.001). Traces of SDS were 
detected in tissue decellularised by both methods 
(D-hSVFLOW, 0.0006 ± 0.0001%/g, n = 5; D-hSVROLLER, 
0.0010 ± 0.0003%/g, n = 5) but there were no differences 
between method (p > 0.05) (Figure 8(b)).
Evaluation of D-hSVs following in vivo 
transplantation in pig
There was no obvious mismatch in lumen diameter and 
wall thickness between D-hSV and native carotid artery at 
surgical transplantation in 5/6 experiments. In experiment 
5, the segment of D-hSV used was moderately dilated 
resulting in a moderate mismatch with the PCA within 
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Table 3. Extracellular matrix composition of hSV tissue lysates following 0.01% SDS (w/v) decellularisation with flow and roller 
protocols.
ECM component Units Native hSV DhSVFLOW DhSVROLLER
Hydroxyproline ng/µg total protein 0.027 ± 0.003 0.021 ± 0.002 0.022 ± 0.003
Elastin 3.733 ± 0.158 3.319 ± 0.171 3.486 ± 0.176
GAGs 0.594 ± 0.063 0.410 ± 0.020 0.398 ± 0.041
ECM: extracellular matrix; GAGs: glycosaminoglycans; hSV: human saphenous vein; DhSV: decellularised hSV.
Values represent mean ± SEM (n = 7).
Figure 7.  Burst strength (a) and compliance (b) of control 
(native) hSV, 0.01% SDS w/v decellularised hSV and porcine 
carotid artery (pCA) and PTFE segments. Values are presented 
as mean ± SEM. Number of samples indicated in graphs.
Figure 8. Effectiveness of the removal of SDS in the flow 
compared to roller decellularisation protocols. (a) The 
concentration of SDS in the effluent for both protocols after 
decellularisation with 0.01% (w/v) SDS (n = 8 per protocol) and 
(b) the residual amount per gram of tissue, in saphenous vein 
(n = 5 per protocol) at the end of the decellularisation protocol 
was determined using the methylene blue assay. Values 
are presented as mean ± SEM. * and # indicate significant 
difference (p < 0.001) compared to 0.01% SDS for flow and 
roller respectively.
excellent with easy passing through of 7-0 prolene stitches 
and no bleeding from the suture line following arterial 
reperfusion at systemic arterial pressure and normal pul-
satility across the graft and distal to it. All six pigs sur-
vived the graft procedure and were extubated within 30 to 
45 min from its completion. Animals gained normal 
weight during the following 4 weeks (mean preoperative 
weights 58.8 ± 1.4 kg vs. 76.3 ± 2.7 kg at explant 
procedure). Three out of six grafts were patent at 4-week 
post-surgery (50%). Of note, 1/3 grafts of the 75 mg aspi-
rin cohort were patent (33%) compared to 2/3 grafts of the 
300 mg aspiring cohort (66%).
Measurement of FFPE sections (Table 4) showed that 
there was no significant vessel inner diameter mismatch 
between D-hSV and native porcine carotid artery prior to 
implant, however the carotid artery had a 1.43 ± 0.12-fold 
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thicker vessel wall (p < 0.05). At 4-weeks post-surgery, 
there was no overall change in inner diameter, however the 
wall thickness had increased in all patent grafts when com-
pared to pre-implanted D-hSV (5.92 ± 0.66 -fold change, 
p < 0.05). The thickness of the graft wall was also thicker 
than that of the native pCA proximal and distal to the 
D-hSV graft (p < 0.05) (the exception being Pig 1, which 
had a thinner graft wall compared to the native distal pCA).
Discussion
We describe the development and validation of a simple, 
rapid and biocompatible method for decellularising hSV 
for possible future use in coronary and/or vascular surgery. 
We utilise low SDS concentration and show that this 
achieves an effective hSV decellularisation with no resid-
ual viable cells (only DNA traces) while preserving the 
ECM composition and the mechanical strength, with 
excellent biocompatibility in vitro and in vivo when using 
an advanced porcine model of carotid artery replacement, 
without immunosuppression.
SDS contains a negatively charged functional group 
making it an anionic surfactant that acts on cell mem-
branes thus disrupting their stability. It is routinely used 
in molecular biology as a cell lysis buffer as it also 
binds to, and eventually denatures, proteins by unfold-
ing the protein 3-dimensional formation. Due to this 
mechanism of action on cells and their proteins, it is 
vital to optimise the exposure time and concentration of 
SDS used to find the right balance between cell removal 
and maintenance of the structural integrity of the decel-
lularised vascular scaffold.
Using SDS 0.01% w/v, we achieved 65% decellularisa-
tion in short hSVs (~0.5 cm), with almost full decellulari-
sation at 0.075% SDS. Schaner et al.,16 also observed 
almost complete cell loss at 0.075% SDS, however at 
0.01% SDS they only achieved 32% cell loss. They carried 
out the decellularisation at 37°C in a shaking waterbath for 
15 h, whereas we used room temperature on a roller for 
24 h. Despite D-hSVs not being completely free of cell 
nuclei, H&E staining showed that residual nuclei were 
much fainter than in controls, implying reduced DNA con-
tent. Noticeably, there was no BrdU uptake by residual 
cells within the D-hSVs after 14-days of cell culture, com-
pared to 81% of cells in untreated vein, hence demonstrat-
ing no cell viability within the D-hSV after treatment.
To ascertain the biocompatibility and translational poten-
tial of our approach we compared the H&E findings of D-hSV 
at 0.01% SDS with two commercially available decellular-
ised biological surgical patches routinely used in clinical 
practice (CorMatrix® ECM® (CorMatrix Cardiovascular, 
Inc., USA) and No-React® Porcine Pericardial Patch 
(Biointegral Surgical Inc., Canada)). This showed that the 
commercially available patches contained noticeably more 
nuclei compared to our D-hSV as a confirmation of the effec-
tiveness of our approach and that residual nuclei do not pre-
clude translation/clinical application.
The content of double-stranded DNA was not affected 
by any of the SDS concentrations tested. Conversely, we 
observed a decrease in fragments of high molecular weight 
DNA at 0.01% SDS. This discrepancy may be explained 
by lab methods used as small <50 bp fragments can be 
detected by the PicoGreen assay, but not by gel electropho-
resis. It is suggested that the minimum criterion for suc-
cessfully denatured DNA in decellularised tissue is <200 
base pairs.8 Fragments <300 bp are reported to be less 
likely to induce inflammatory and tissue remodelling, with 
DNA fragments of this size found in commercially avail-
able scaffolds.17 Other studies have shown only 10% of 
DNA remains after SDS decellularisation of porcine myo-
cardium, heart valve, small intestine submucosa and 
lung.18–20 However, these studies used much higher con-
centrations of SDS (0.1%–1% w/v). We could have added 
DNAses in our method to break down the DNA within 
hSV as done by others for different tissues,21 however 
DNAses have been shown to reduce mechanical stability 
and reduce GAG content of tissue, compared to methods 
incorporating DNAses.21 In addition, we believe this 
approach could have impacted negatively on the biocom-
patibility of D-hSVs, as incomplete removal of DNAses 
would have affected the cell seeding/proliferation, and 
longer wash steps would have been required for complete 
Table 4. Morphological analysis of vessels taken at time of graft implant, or at 4 weeks post-implant (n = 6).
Conduit Inner diameter (µm) Wall thickness (µm)
Pre-implant Native hSV 1875 ± 207 622 ± 31
DhSV 2068 ± 193 463 ± 30
Native PCA 2412 ± 339 658 ± 56*
Explanted tissue DhSV Graft 2987 ± 1294 2802 ± 421*
PCA Proximal 2457 ± 607 864 ± 142†
PCA Distal 1371 ± 443 974 ± 175†
PCA: porcine carotid artery; hSV: human saphenous vein; DhSV: decellularised hSV.
Measurements were carried out on images of EVG stained formalin-fixed paraffin-embedded sections (n = 3).
*p < 0.05 versus pre-implant DhSV.
†p < 0.05 versus explanted DhSV Graft.
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removal, potentially making the method less attractive 
translationally.
The preservation of the integrity of the ECM was evalu-
ated using both histological staining for collagen, elastin 
and GAGs, alongside assays for hydroxyproline (as a major 
component of collagen), elastin, and GAGs. The only sig-
nificant change in ECM integrity we observed was a 
decrease in hydroxyproline content at 0.05% SDS concen-
tration. This finding was not seen with collagen staining, 
however differences in sensitivity between the assay and 
histological staining could account for this. Also, staining 
was carried out on 5 µm thick tissue sections, compared to 
approximately 100 µm thick pieces of tissue used in the 
assay. There was also a trend for decrease in elastin content 
at 0.025% SDS, but this was not significant.
We reasoned that 0.5 cm segments of hSV have very 
little potential for clinical applications and therefore 
thought to validate these findings on longer hSV segments 
(4–6 cm) using the 0.01% SDS concentration and expose 
them to roller agitation and flow perfusion settings, as per-
fusion methods are commonly used to decellularise heart, 
lung, liver and kidneys.22–24 We observed that the amount 
of decellularisation obtained was greater with the roller 
than with the flow apparatus, while DNA content did not 
differ in line with what observed for the short hSVs. 
Similarly, the perfusion method did not disrupt the ECM as 
levels of hydroxyproline, elastin or GAGs did not change 
and were comparable to those observed with the roller. 
However, it should be mentioned that we used a low flow 
system. High flow systems, possibly pulsatile, might have 
been more effective particularly when thinking that CABG 
surgery require SV of at least 12 to 15 cm25,26 that might be 
better decellularised by using high flow systems.
For the evaluation of residual mechanical strength of 
D-hSVs we used the burst strength and circumferential 
compliance. These methods are important indicators of 
graft suitability before proceeding to ex vivo flow assess-
ment, or in vivo arterial models. In both cases, we found 
no significant differences between D-hSVs, untreated hSV, 
or untreated PCA. It has been shown that hSV and IMA 
have average burst pressures of 2134 mmHg (≡285 kPa) 
and 3073 mmHg (≡410 kPa) respectively, with the com-
pliance of the vessels being 11.5%/100 mmHg (IMA) and 
25.6%/100 mmHg (hSV).4 In the present study, D-hSVs 
had a higher burst pressure (436 kPa) and only 
8.23%/100 mmHg compliance than untreated hSV con-
trols. This confirmed the suitability of the D-hSVs as grafts 
for ex vivo and in vivo evaluations. In our case, the burst 
pressure (537 kPa) and compliance (13.7 mmHg) of the pig 
carotid artery were not significantly different to that of 
D-hSV supporting the safety of an in vivo implant in pig 
and as a good base for arterial tissue engineering.
The level of cytotoxicity of SDS varies between cell 
types with the threshold being 0.002% for human bronchial 
epithelial cells, lung fibroblasts and mesenchymal cells and 
0.00012% for human pulmonary vascular endothelial 
cells.27 Mathapati et al.28 suggested that 0.1% SDS equates 
to a residual content of only 0.8 mg/g of implanted SV. In 
this study, we observed residual SDS of 0.0006%/g and 
0.0010%/g of tissue for flow versus roller methods respec-
tively. This equates to 0.6 mg/g and 1.0 mg/g respectively. 
These trace of SDS did not have a significant cytotoxic 
effect in vitro when these D-hSVs were seeded with porcine 
endothelial cells and smooth muscle cells in culture, or 
when their biocompatibility was assessed by seeding with 
human ADSC, HUVEC and HSVSMC. When added 
directly to porcine cells in culture, concentrations greater 
than 0.00025% SDS (PCAEC) and 0.0005% SDS 
(PCASMC) had a detrimental effect on cell viability, which 
fell below the ISO standard threshold of 70% of control 
cells. The proliferative capacity of cells was impaired at 
0.00075% SDS for both PCAEC and PCASMC. On balanc-
ing viability and proliferation rates, endothelial cells 
appeared more susceptible to SDS cytoxicity at low concen-
tration than SMCs. However, this may not be an issue as 
endothelial cells lining the lumen are in contact with D-hSVs 
only on the basal cell surface. With regard to methods of 
decellularisation used, the SDS levels found in D-hSVFLOW 
should not affect cellular proliferation, whereas those found 
with D-hSVROLLER may reduce it. All the cell types seeded 
were viable, and among them HSVSMC significantly pro-
liferated. HUVEC did not proliferate beyond the 48 h time-
period, but this is to be expected, as once endothelial cells 
come into contact with each other and form a monolayer 
they exit the cell cycle and do not grow or proliferate fur-
ther.29 PCAEC survived on D-hSVs regardless of the decel-
lularisation protocol used with some CD31 positive cells 
observed within the wall of D-hSVsROLLER, along some 
positive SMC actin staining observed in absence of SMCs 
seeding, which warrant further investigation.
We undertook xenotransplantation of D-hSVs in pigs 
with no immunosuppression. In the first cohort of three 
pigs we used 75 mg of daily aspirin with food. This was 
associated with a patency rate at 4 weeks of 33% (2/3 
grafts fully thrombosed). In the second cohort of three 
experiments we used 300 mg of aspirin daily with food, 
also in line with clinical recommendations.30 In this sec-
ond cohort the graft patency rate was 66% at 4 weeks (1/3 
graft thrombosed), giving an overall patency rate of 50%, 
with a significant infiltration of the D-hSV grafts by host 
porcine cells. There was no mechanical failure of any of 
the grafts implanted and excellent suturability with no 
bleeding from the suture lines.
In conclusion, we have developed a simple and rapid 
methodology to effectively decellularise hSVs. This approach 
allows to obtain a tissue engineered acellular vascular scaf-
fold with excellent biocompatibility and mechanical strength 
to enhance safe use for autologous or allogeneic clinical 
applications. We identify a low SDS concentration that 
achieves an effective balance between hSV decellularisation 
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with no residual viable cells while preserving the integrity of 
the ECM composition. Preliminary in vivo feasibility testing 
in pig, in terms of mechanical safety and patency rates showed 
remarkable results when considering that these were xeno-
transplants with no immunosuppression used. The approach 
used here has great potential both as a pre-clinical graft test-
ing model, and in the clinical setting, as even during 
xenotransplantation without immunosuppression, the results 
are extremely positive. Autologous veins or those from a 
deceased donor could be harvested, and the resulting decel-
lularised hSV may then undergo sophisticated arterial tissue 
engineering prior to surgical implantation for example, graft 
molecular functionalisation to harness host cells to ehance 
additional in-situ arterial tissue engineering.
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